Antimicrobial Activity of Brassica rapa L. Flowers Extract on Gastrointestinal Tract Infections and Antiulcer Potential Against Indomethacin-Induced Gastric Ulcer in Rats Supported by Metabolomics Profiling

Badriyah Alotaiby1,*, Fatma Alzahraa Mokhtar2,*, Thanaa A El-Masry3, Engy Eleknawy4, Sally A Mostafa5, Dalia H Abdelkader6, Mohamed E Elharty7, Asmaa Saleh8,9, Walaa A Negm9

1Department of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah Bint Abdulrahman University, Riyadh, 84428, Saudi Arabia; 2Department of Pharmacognosy, Faculty of Pharmacy, AL-Salam University, Al Gharbiyah, Egypt; 3Department of Pharmacology and Toxicology, Faculty of Pharmacy, Tanta University, Tanta, 31111, Egypt; 4Pharmaceutical Microbiology, Department, Faculty of Pharmacy, Tanta University, Tanta, 31111, Egypt; 5Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Mansoura University, Mansoura, 35511, Egypt; 6Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, 31111, Egypt; 7Study Master in Pharmaceutical Science at the Institute of Research and Environmental Studies, El Sadat City, Egypt; 8Department of Biochemistry, Faculty of Pharmacy, Al Azhar University, Cairo, Egypt; 9Department of Pharmacognosy, Faculty of Pharmacy, Tanta University, Tanta, 31111, Egypt

*These authors contributed equally to this work

Introduction: The gastrointestinal tract (GIT) is vulnerable to various diseases. In this study, we explored the therapeutic effects of Brassica rapa flower extract (BRFE) on GIT diseases.

Methods: Liquid chromatography–electrospray ionization–tandem mass spectrometry (LC-ESI-MS/MS) was used for phytochemical identification of the compounds in BRFE. The antibacterial activity of BRFE was investigated, and its impact on the bacterial outer and inner membrane permeability and membrane depolarization (using flow cytometry) was studied. In addition, the immunomodulatory activity of BRFE was investigated in vitro on lipopolysaccharide (LPS)-stimulated peripheral blood mononuclear cells (PBMCs) using quantitative reverse transcription polymerase chain reaction (qRT-PCR). Furthermore, the anti-inflammatory activity of BRFE was investigated by histopathological examination and qRT-PCR on indomethacin-induced gastric ulcers in rats.

Results and Discussion: LC-ESI-MS/MS phytochemically identified 57 compounds in BRFE for the first time. BRFE displayed antibacterial activity against bacteria that cause GIT infections, with increasing outer and inner membrane permeability. However, membrane depolarization was unaffected. BRFE also exhibited immunomodulatory activity in LPS-stimulated PBMCs by attenuating the upregulation of cyclooxygenase 2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), and nuclear factor kappa B (NF-kB) gene expression compared with untreated LPS-stimulated PBMCs. In addition, BRFE exhibited anti-inflammatory activity required for maintaining gastric mucosa homeostasis by decreasing neutrophil infiltration with subsequent myeloperoxidase production, in addition to an increase in glutathione peroxidase (GPx) activity. Histopathological findings presented the gastroprotective effects of BRFE, as a relatively normal stomach mucosa was found in treated rats. In addition, BRFE modulated the expression of genes encoding IL-10, NF-kB, GPx, and myeloperoxidase (MPO).

Conclusion: BRFE can be a promising source of therapeutic agents for treatment of GIT diseases.

Keywords: antioxidant activity, flow cytometry, GIT diseases, immunomodulatory activity, LC-MS/MS, qRT-PCR
Introduction
Various plants contain many chemical compounds with wide structural diversity and good biological activity against different diseases. Therefore, many scientists have focused their research on elucidation of the biological activity of different plant extracts to find new alternative therapeutic agents against various diseases. Gastrointestinal tract (GIT) diseases are any disorders in the digestive tract that extends from the oral cavity to the rectum. GIT diseases, unfortunately, have a relatively high prevalence worldwide. Many drugs currently available for treatment of GIT diseases have disadvantages of low efficacy or high rates of side effects. Hence, many studies have investigated the potential therapeutic activity of different plants in GIT diseases.

Brassica rapa L. (turnip; family Cruciferae) is one of the first vegetables to be cultivated worldwide. Due to its nutritional characteristics, it is a popular crop for its edible components, including leaves, roots, and flowers, which are consumed in large amounts. B. rapa L. has been used for centuries to cure a number of disorders, including hepatitis, jaundice, diabetes, sore throat, constipation, and cholecystitis. In addition, it is used for lung protection and nephroprotection in Unani and Arab traditional medicine.

B. rapa L. is reported to have a variety of secondary metabolites, such as glucosinolates, isothiocyanates, flavonoids, phenylpropanoids, sulfur-containing compounds, phenolics, indoles, and carbohydrates. Its reproductive organs have the largest quantity of glucosinolates and nitrogen-containing chemicals, whereas volatile substances (terpenes and isoprenoids) are prevalent in seedlings and decrease with development. Progoitrin, gluconapoleiferin, gluconapin, 4-hydroxyglucobrassicin, glucobrassicinapin, glucobrassicin, gluconasturtiin, and neoglucobrassicin are the most prominent glucosinolates. B. rapa L. greens and tops contain flavonoids, primarily quercitin, kaempferol, and isorhamnetin derivatives. These major, active constituents of B. rapa L. show diverse bioactivities, including antioxidant, hepatoprotective, anticancer, antimicrobial, anti-diabetic, nephroprotective, cardioprotective, hypolipidemic, analgesic, and anti-inflammatory effects.

To date, different plant extracts have been established as prospective therapeutic agents for the treatment of different GIT diseases. In this study, we evaluated the potential antimicrobial activity of B. rapa flower extract (BRFE) on the bacteria that cause GIT infections. Additionally, previous studies have shown the anti-inflammatory and gastroprotective effects of some Brassica species, which motivated us to conduct in vivo anti–gastric ulcer studies on BRFE. Moreover, we also investigated BRFE’s in vitro immunomodulatory activity and explored the phytochemical profiling of BRFE’s secondary metabolites.

Materials and Methods
Preparation of BRFE
B. rapa L. specimens were gathered from Al Keram Farms, El-Beheira Governorate, Egypt, in February 2021. The plant was recognized by Dr. Wafaa Amer at the Plant Taxonomy Department, Faculty of Science, Cairo University, Egypt. A voucher sample (PG-MF-0089) was deposited at the herbarium of the Pharmacognosy Department, Tanta University, Egypt. The specimens were dried at room temperature for 10 days and then powdered. The powder (350 g) was extracted with 80% methanol (3 L × 3 times) using the cold maceration method to yield 50.3 g of BRFE.

Chemicals
Indomethacin was obtained from Kahira Pharmaceutical & Chemical Industries Co. (Egypt). Other chemicals, including dimethyl sulfoxide (DMSO), resazurin, N-phenyl-1-naphthylamine (NPN), o-nitrophenyl-β-D-galactopyranoside (ONPG), DiBAC4(3), Roswell Park Memorial Institute 1640 (RPMI 1640), fetal bovine serum (FBS), L-glutamine, and penicillin-streptomycin solution, were obtained from Merck (USA).

Animals
In total, 60 Sprague–Dawley rats were acclimatized for 2 weeks in wire cages with free access to water and a regular pellet diet. The rats’ starting weight was 230–250 g, and their age was 12 weeks.

LC-MS/MS for Metabolite Profiling
Liquid chromatography–electrospray ionization–tandem mass spectrometry (LC-ESI-MS/MS) analysis was conducted at the Children’s Cancer Hospital’s Proteomics and Metabolomics Unit (57357). Adopting the criteria described by Attallah et al. for high-performance liquid-chromatography separation, a Waters reversed-phase X select HSS T3 column (diameter 2.1 mm, length 150 mm, 2.5μ m), a precolumn (Phenomenex), and inline filter disks (0.5μ m × 3.0 mm) were used. To identify chemicals, PeakView™ software was used to compare retention duration and m/z values obtained by MS/MS². The XIC Manager in PeakView™ software was used to calculate peak area values. Extracted ion chromatograms
Bacterial isolates were overnight grown in Mueller–Hinton broth (MHB) supplemented with 2% lactose and then centrifuged. After washing the pellets, they were resuspended in 0.5% NaCl. Next, 34 mmol ONPG was added to the bacterial suspensions (before and after treatment with BRFE at 0.5 MIC). The optical density (OD) was monitored at 420 nm to assess the ONPG degradation by β-galactosidase.

Impact on the Bacterial Membrane Depolarization

Membrane depolarization was studied in the tested isolates before and after treatment with BRFE at 0.5 MIC using the fluorescent dye DiBAC4(3). This fluorescent compound can enter depolarized cells, where it displays increased fluorescence because it binds to intracellular proteins. After staining the tested isolates with 5 μg/mL of DiBAC4(3), they were examined using a FACSVerse flow cytometer (BD Biosciences, USA).

Immunomodulatory Activity

Isolation of Peripheral Blood Mononuclear Cells

Peripheral blood mononuclear cells (PBMCs) were isolated from the blood of healthy donors using Ficoll density gradient centrifugation. Then, they were cultured in flat-bottom 6-well plates in RPMI 1640 medium supplemented with 2 mM L-glutamine, 10% FBS, and 1% penicillin-streptomycin solution. They were incubated for 24 h at 37°C in a humidified atmosphere containing 5% CO₂.

MTT Cell Viability Assessment

The toxicity of BRFE (concentrations of 3.125, 6.25, 12.5, 25, 50, 100, 200, and 400 μg/mL) on PBMCs was assessed using the MTT viability test. The median inhibitory concentration (IC₅₀) of BRFE against PBMCs was determined. In addition, the immunomodulatory activity of BRFE was tested in lipopolysaccharide (LPS)-stimulated PBMCs at 0.5 IC₅₀.

Quantitative Real-Time PCR

The impact of BRFE on the gene expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), interleukin (IL)-6, tumor necrosis factor-alpha (TNF-α), and nuclear factor kappa B (NF-kB) in LPS-stimulated PBMCs was studied. Briefly, 2×10⁶ cells/mL of PBMCs were cultured in flat-bottom 6-well plates in RPMI 1640 medium for 24 h and then treated with 100 μL of Escherichia coli LPS (20 ng/mL) for 24 h in the presence and absence of BRFE at 0.5 IC₅₀. The impact on the gene expression of COX-2, iNOS, IL-6, TNF-α, and NF-kB was evaluated by quantitative reverse transcription polymerase chain reaction (qRT-PCR; primers...
are displayed in Table S1). Total RNA was extracted from PBMCs using the RNeasy mini kit (Qiagen, Hilden, Germany) and then converted to complementary DNA (cDNA) using the SensiFAST™ cDNA kit (Bioline, London, UK). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an internal control gene, and the SensiFAST™ SYBR green PCR master mix (Bioline) was used. To calculate the fold-change in the gene expression, we used the $2^{-\Delta\Delta CT}$ method.28

In vivo Antiulcer Activity
Ulcer Induction
For ulcer induction, Sprague–Dawley rats were administered a single dose of 100 mg/kg of indomethacin dissolved in distilled water via gavage. Briefly, the 60 rats were randomly divided into 4 groups: group 1 (control, n = 15), group 2 (ulcer group, n = 15), group 3 (150 mg/kg of BRFE, n = 15) and group 4 (300 mg/kg of BRFE, n = 15).

The utilized doses of BRFE were based on previous biological investigations for the same species using different plant organs.29,30 Groups 3 and 4 (pretreatment groups) were administered 150 and 300 mg/kg of BRFE, respectively, orally via gavage daily for 10 days. On day 10, before administering indomethacin, all rats were fasted for 24 h and housed in big wire mesh-bottom cages to prevent coprophagia. Water access was also restricted for 2 h. The rats were given 100 mg/kg of indomethacin by single gavage for ulcer induction 1 h after treatment. Groups 1 and 2 (given the vehicle instead of either drug for the first 10 days) were given the vehicle and indomethacin, respectively, at the same time on the final day.

All rats were euthanized using ether, and their stomachs were excised before indomethacin dosage and 4 h after indomethacin/vehicle gavage.

Biochemical Studies
Gastric Glutathione and Malondialdehyde Levels Measurement
To prepare tissue for assaying stomach glutathione (GSH) and malondialdehyde (MDA) levels, 250 mg of stomach tissue was homogenized in 2.5 mL of potassium phosphate buffer (pH 7.4) using a PT 3100 homogenizer (Polytron, Zurich, Switzerland) and centrifuged at 4000 rpm for 15 min at 4°C. The level of decreased GSH in the stomach tissue homogenate was measured colorimetrically using a Biodiagnostics kit (Egypt), as previously described.32 Thiobarbituric acid interacted with MDA in the sample in an acidic medium at 95°C for 30 min. Then, the absorbance of the formed pink compounds was measured at 534 nm using a Unico 2100 spectrophotometer. MDA levels were expressed as nmol/g using the following equation:

$$\text{MDA concentration} = \frac{A_{\text{sample}} \times 10}{A_{\text{standard}} \times \text{weight tissue used (g)}} \text{nmol/g}$$

Nitric Oxide Levels Measurement
To assay stomach nitric oxide (NO) levels, 250 mg of stomach tissue was homogenized in 2.5 mL of ice-cold normal saline (0.9%). Then, 1 mL of absolute ethanol was added to 0.5 mL of the homogenate to precipitate proteins, and the sample was centrifuged at 3000 rpm for 10 min at 4°C. The nitrite (an indicator of the original NO present) in the stomach was measured to estimate the amount of NO present. In a nutshell, 500 µL of the homogenate supernatant was combined with an equal amount of VCl3 and Griess reagent (0.2% naphthyl ethylene-diamine and 2% sulphanilamide in 5% hydrochloric acid). After 30 min of incubation at 37°C, the absorbance of the mixture was measured at 540 nm using a spectrophotometer.33 The nitrite concentration in the sample was calculated and expressed as nmol NO/g tissue in comparison with sodium nitrite standards.33

Determination of Prostaglandin E2
The prostaglandin E2 (PGE2) level in the stomach tissue homogenate supernatant was determined using enzyme-linked immunosorbent assay (ELISA; Mouse PGE2 ELISA Kit NOVA) according to the manufacturer’s instructions (Bioneovan Co., China).

qPCR
The relative gene expression of IL-10, glutathione peroxidase (GPx), NF-κB, and myeloperoxidase (MPO) was detected at 405 nm using a Unico 2100 spectrophotometer (Phoenix, USA). The GSH levels were displayed as mg/g tissue using the following equation:

$$\text{GSH concentration in tissue} = \frac{A_{\text{sample}} \times 66.66}{\text{weight tissue used (g)}} \text{mg/g}$$
Histopathological Studies
For histological analysis of the stomach of rats, stomach tissue was preserved in 10% formalin for 24 h, embedded in paraffin blocks, serially sectioned to 5 mm thickness using a RM2135 microtome (Leica, Germany), mounted on glass slides, stained with hematoxylin and eosin, and examined using a light microscope (Labomed, USA).

Institutional Review Board Statement
The study was conducted according to the guidelines approved by the research ethics committee of the Faculty of Pharmacy, Tanta University, for the care and use of laboratory animals (approval code TP/RE/10-21-P-001).

Statistical Analysis
All tests were repeated thrice, and the results are presented as means ± standard deviation using SPSS Statistics version 26 (IBM Corp., USA). Parameters that were acquired from the different tested groups were compared with each other using analysis of variance; \(p < 0.001\) was considered statistically significant.

Results
LC-ESI-MS/MS of BRFE
The analysis of BRFE using MS-DIAL in LC-MS/MS (negative- and positive-mode ESI) as a modern analytical technique tentatively identified 57 secondary metabolites. The identified metabolites were classified as anthocyanidin-3-O-glycosides, alkaloids, aurone derivative, coumarins, flavonoid aglycone, flavonoid glycoside, phenolic acid, and carboxylic acid. Table 1 shows the results of LC-ESI-MS/MS analysis of BRFE metabolites, and Figure 1 shows the total ion chromatogram of BRFE.

Identification of Simple Phenols and Phenolic Acid Derivatives
Simple phenols are represented by three main classes (hydroxy coumarins, hydroxybenzoic acid, hydroxycinnamic acids) and their corresponding derivatives. Two hydroxyl coumarins were identified in negative ion mode ([M-H]) as 7-hydroxy-4-methyl coumarin scopoletin and daphnetin at \(m/z\) 174.95, 177.05, and 193.05, respectively. \(p\)-Hydroxybenzoic acid was identified in [M-H] at \(m/z\) 137, and the identified hydroxycinnamic acids and their derivatives identified were [5, 11, 15, 21, 22, 37]. Caffeic acid was found to be the most abundant hydroxycinnamic acid in the chromatogram in [M-H] at \(m/z\) 179, followed by 1-O-\(\beta\)-D-glucopyranosyl sinapate in [M-H] at \(m/z\) 385.

Identification of Flavonoids
Flavonoid glycosides detected in BRFE were tentatively identified as isorhamnetin, baicalein, daidzein, kaempferol, luteolin, naringenin, okanin, and rhoifolin glycosides. The identified compounds in [M-H] were [10, 12, 13, 16, 17, 23, 26, 27, 29, 33, 35, 36, 42, 43, 44, 45] at \(m/z\) 445.14, 449.11, 625.12, 609.15, 447.09, 447.07, 593.12, 623.16, 415.13, 447.09, 477.1, 479.12, 431.1, 435.13, 577.15, and 481.10, respectively. Isorhamnetin-3-O-glucoside was the major identified compound in [M-H] according to peak area measurements at \(m/z\) 477 and MS/MS at \(m/z\) 315 [M-H-glc] and 299 [M-H-glc-HOCH3], and 285 [M-H-glc-OH] (Figure 2A), followed by kaempferol-3-O-glucoside, luteolin-3', and 7-di-O-glucoside in the same order. The identified compounds in positive ion mode ([M+H]) were [13, 23, 26, 27, 29, 43, 45] at \(m/z\) 627, 425, 479, 435, and 481, respectively. Isorhamnetin-3-O-glucoside was the major identified compound in [M+H] according to peak area measurements at \(m/z\) 479 and MS/MS at \(m/z\) 317 [M+H-glc]+ and 301 [M+H-glc-H2O]+ (Figure 2C). The flavonoid aglycones were represented by nine compounds: [31, 49, 50, 51] in [M-H] and [47, 52, 53, 54, 55] in [M+H]. The major aglycones were naringenin, luteolin, and quercetin.

Identification of Anthocyanidin-3-O-Glycosides
Tentative identification of anthocyanidin-3-O-glycosides in BRFE provided insights into the compounds responsible for the characteristic yellow color of most flowers of the family Brassicaceae. Delphinidin, cyanidin, and petunidin glycosides were the most abundant anthocyanins in [M-H] at \(m/z\) 611, 479, 449, and 933, respectively, and compounds [25, 30] in [M-H] at \(m/z\) 609 and 449, respectively, according to peak area measurement of the spectrum. In addition, delphinidin-3-O-\(\beta\)-glucopyranoside was the major anthocyanin glycoside detected in [M-2H]+ at \(m/z\) 463.09 with characteristic MS/MS at \(m/z\) 271 and 301 [M-2H-glc]+ (Figure 2B), followed by cyanidin-3-O-[(2''-O-\(\beta\)-glucopyranosyl-\(\beta\)-glucopyranoside) in [M-2H]+ at \(m/z\) 609.15 with characteristic MS/MS at \(m/z\) 227.03, 255.02, 285.03, 463.08 (Figure 2D). Cyanidin-3,5-di-O-glucoside was the major anthocyanidin detected in [M]+ at \(m/z\) 611.16 with MS/MS at \(m/z\) 449 [M-glc]+ and 287 [M-glc-glc]+.
<table>
<thead>
<tr>
<th>Peak No.</th>
<th>Identification</th>
<th>RT (Min.)</th>
<th>m/z</th>
<th>Peak Height</th>
<th>Peak Area</th>
<th>Ion Mode</th>
<th>Formula</th>
<th>MS/MS</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>* Succinic acid</td>
<td>1.0788</td>
<td>117.02</td>
<td>41,611.6</td>
<td>572,629.8</td>
<td>[M-H]</td>
<td>C_4H_6O_4</td>
<td>73.02, 99.00</td>
<td>[34]</td>
</tr>
<tr>
<td>2</td>
<td>^ D-(+)-Malic acid</td>
<td>1.0913</td>
<td>133.01</td>
<td>810,402</td>
<td>13,089,116</td>
<td>[M-H]</td>
<td>C_4H_6O_4</td>
<td>71.01, 87.00, 114.63</td>
<td>[35]</td>
</tr>
<tr>
<td>3</td>
<td>* Maleic acid</td>
<td>1.0951</td>
<td>115</td>
<td>141,150</td>
<td>2,155,713</td>
<td>[M-H]</td>
<td>C_4H_6O_4</td>
<td>71.01</td>
<td>[36]</td>
</tr>
<tr>
<td>4</td>
<td>p,a-p-Hydroxybenzoic acid</td>
<td>1.1412</td>
<td>137.02</td>
<td>4951.78</td>
<td>39,562.14</td>
<td>[M-H]</td>
<td>C_7H_8O_3</td>
<td>73.02, 95.64</td>
<td>[37]</td>
</tr>
<tr>
<td>5</td>
<td>p,a- Caffeic acid</td>
<td>1.2297</td>
<td>179.05</td>
<td>51,602.8</td>
<td>768,577.1</td>
<td>[M-H]</td>
<td>C_8H_6O_4</td>
<td>71.05, 75.00, 161.04</td>
<td>[38]</td>
</tr>
<tr>
<td>6</td>
<td>p,a- Sinapyl aldehyde</td>
<td>1.2391</td>
<td>208.97</td>
<td>50,736</td>
<td>403,100.7</td>
<td>[M+H]^+</td>
<td>C_11H_12O_4</td>
<td>104.10, 191.95</td>
<td>[39]</td>
</tr>
<tr>
<td>7</td>
<td>p,a- Sinapoyl malate</td>
<td>1.3058</td>
<td>339.07</td>
<td>45,705.9</td>
<td>428,045.8</td>
<td>[M+H]</td>
<td>C_13H_14O_9</td>
<td>115.00, 159.02, 223.06</td>
<td>[39]</td>
</tr>
<tr>
<td>8</td>
<td>p,a- Syringetin-3-O-galactoside</td>
<td>1.345</td>
<td>507.14</td>
<td>7179.44</td>
<td>46,241.8</td>
<td>[M-H]</td>
<td>C_23H_24O_13</td>
<td>165.03, 299.06, 461.11</td>
<td>[40]</td>
</tr>
<tr>
<td>9</td>
<td>p,a- Nicotinic acid</td>
<td>1.7833</td>
<td>122.02</td>
<td>5104.44</td>
<td>41,389.61</td>
<td>[M-H]</td>
<td>C_6H_4NO_2</td>
<td>78.03</td>
<td>[41]</td>
</tr>
<tr>
<td>11</td>
<td>p,a- 3-(4-Hydroxy-3-methoxy phenyl) prop-2-enoic acid</td>
<td>4.1608</td>
<td>195.06</td>
<td>2148.33</td>
<td>35,963.14</td>
<td>[M+H]^+</td>
<td>C_10H_12O_4</td>
<td>89.03, 149.02, 163.03, 177.05</td>
<td>[43]</td>
</tr>
<tr>
<td>12</td>
<td>f,a Olanin-4’-O-glucoside</td>
<td>4.2895</td>
<td>449.11</td>
<td>3360.78</td>
<td>46,512.64</td>
<td>[M-H]</td>
<td>C_21H_20O_11</td>
<td>167.03, 361.09, 403.19</td>
<td>[44]</td>
</tr>
<tr>
<td>13</td>
<td>f,a Quercetin-3,4’-O-di-β-glucopyranoside</td>
<td>4.5287</td>
<td>625.12</td>
<td>16,840.6</td>
<td>69,874.74</td>
<td>[M+H]-</td>
<td>C_21H_20O_17</td>
<td>299.02, 301.03, 463.09</td>
<td>[45]</td>
</tr>
<tr>
<td>14</td>
<td>f,a Quercetin-3,4’-O-di-β-glucopyranoside</td>
<td>4.537</td>
<td>627.15</td>
<td>57,862.4</td>
<td>751,367.8</td>
<td>[M+H]^+</td>
<td>C_21H_20O_17</td>
<td>127.03, 227.03, 303.04, 465.09</td>
<td>[45]</td>
</tr>
<tr>
<td>15</td>
<td>p,a- 3-(4-Hydroxyphenyl) prop-2-enoic acid</td>
<td>4.8291</td>
<td>165.05</td>
<td>3065.56</td>
<td>44,606.8</td>
<td>[M+H]^+</td>
<td>C_6H_4O_4</td>
<td>91.01, 119.04</td>
<td>[46]</td>
</tr>
<tr>
<td>17</td>
<td>f,a Quercitrin</td>
<td>5.0023</td>
<td>447.09</td>
<td>1373</td>
<td>9518.728</td>
<td>[M-H]</td>
<td>C_21H_20O_11</td>
<td>357.17889.36, 447.07562.71</td>
<td>[48]</td>
</tr>
<tr>
<td>18</td>
<td>an Cynidin-3, 5-di-O-glucoside</td>
<td>5.0564</td>
<td>611.16</td>
<td>62,284.1</td>
<td>621,277.4</td>
<td>[M]</td>
<td>C_21H_20O_16</td>
<td>109.03, 145.04, 287.05, 449.10</td>
<td>[49]</td>
</tr>
<tr>
<td>19</td>
<td>an Petunidin-3-O-β-glucopyranoside</td>
<td>5.2046</td>
<td>479.1</td>
<td>10,728</td>
<td>79,983.64</td>
<td>[M]</td>
<td>C_21H_20O_12</td>
<td>229.03, 285.04, 317.06</td>
<td>[49]</td>
</tr>
<tr>
<td>20</td>
<td>p,a Rosmarinic acid</td>
<td>5.2738</td>
<td>359.09</td>
<td>5802.67</td>
<td>29,515.36</td>
<td>[M-H]</td>
<td>C_18H_16O_8</td>
<td>151.04201, 71,359.09827.71</td>
<td>[50]</td>
</tr>
<tr>
<td>No.</td>
<td>Compound Description</td>
<td>M.W.</td>
<td>M.H.</td>
<td>M.H.</td>
<td>M.</td>
<td>M.</td>
<td>M.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>--------------------------------------------------------------------------------------</td>
<td>-------</td>
<td>--------</td>
<td>--------</td>
<td>-----</td>
<td>-----</td>
<td>-----</td>
<td></td>
<td></td>
</tr>
<tr>
<td>21</td>
<td><strong>p.a</strong> 3-(4-Hydroxy-3,5-dimethoxyphenyl)-2-propenoic acid</td>
<td>53.157</td>
<td>225.08</td>
<td>11,596.3</td>
<td>157,515.5</td>
<td>[M+H]⁺</td>
<td>207,03</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22</td>
<td><strong>p.a</strong> 1-O- D-glucopyranosyl sinapate</td>
<td>54.676</td>
<td>385.18</td>
<td>13,682.3</td>
<td>76,078.68</td>
<td>[M-H]⁻</td>
<td>112,98, 153.09, 223.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>23</td>
<td><strong>f.e</strong> Luteolin-7-O-glucoside</td>
<td>55.648</td>
<td>447.07</td>
<td>5537.44</td>
<td>34,385.34</td>
<td>[M-H]⁻</td>
<td>242,94, 283.03</td>
<td></td>
<td></td>
</tr>
<tr>
<td>24</td>
<td><strong>f.e</strong> Hyperoside</td>
<td>5.8922</td>
<td>465.1</td>
<td>4772.11</td>
<td>53,492.11</td>
<td>[M+H]⁺</td>
<td>165,02, 177.06, 285.09, 303.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td><strong>an</strong> Cyanidin-3-O-(2”-O-/ β-glucopyranosyl- / -glucopyranoside)</td>
<td>6,0085</td>
<td>609.15</td>
<td>259,006</td>
<td>2,543,264</td>
<td>[M-2H]⁻</td>
<td>227,03, 255,02, 285.03, 463.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>26</td>
<td><strong>f.e</strong> Kaempferol-3-O-(6-p-coumaroyl)-glucoside</td>
<td>6,2881</td>
<td>593.12</td>
<td>4087.11</td>
<td>21,694.75</td>
<td>[M-H]⁻</td>
<td>285,04, 431.14, 477.10, 593.13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>27</td>
<td><strong>an</strong> Kaempferol-7-neohesperidoside</td>
<td>6,3006</td>
<td>593.15</td>
<td>7667.44</td>
<td>84,508.66</td>
<td>[M-H]⁻</td>
<td>283,04, 315.04, 477.10, 593.13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>28</td>
<td><strong>an</strong> Cyanidin-3-glucoside</td>
<td>6,4017</td>
<td>449.11</td>
<td>17,978.4</td>
<td>105,474.4</td>
<td>[M⁺]</td>
<td>85.01, 147.02, 201.02, 287.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>29</td>
<td><strong>f.e</strong> Isorhamnetin-3-O-rutinoside</td>
<td>6,4247</td>
<td>623.16</td>
<td>25,125.9</td>
<td>303,505.5</td>
<td>[M-H]⁻</td>
<td>300.04, 315.06, 477.09, 623.16</td>
<td></td>
<td></td>
</tr>
<tr>
<td>30</td>
<td><strong>an</strong> Pelphinidin-3-O- / β-glucopyranoside</td>
<td>6,5616</td>
<td>463.09</td>
<td>375,374</td>
<td>3,329,388</td>
<td>[M-2H]⁻</td>
<td>271,02, 286.93, 301.03, 461.55</td>
<td></td>
<td></td>
</tr>
<tr>
<td>31</td>
<td><strong>f</strong> Hesperetin</td>
<td>6,6146</td>
<td>301.2</td>
<td>4189.44</td>
<td>19,663.35</td>
<td>[M-H]⁻</td>
<td>175,03, 255.23, 301.19</td>
<td></td>
<td></td>
</tr>
<tr>
<td>32</td>
<td><strong>f</strong> Scopoletin</td>
<td>6,9719</td>
<td>190.95</td>
<td>11,402</td>
<td>48,154.79</td>
<td>[M-H]⁻</td>
<td>117,04, 148.01, 176.008</td>
<td></td>
<td></td>
</tr>
<tr>
<td>33</td>
<td><strong>f</strong> Daidzein-8-C-glucoside</td>
<td>7,0587</td>
<td>415.13</td>
<td>6371</td>
<td>39,787.53</td>
<td>[M-H]⁻</td>
<td>207,05, 415.11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td><strong>p.a</strong> Chlorogenic acid</td>
<td>7,1565</td>
<td>355.15</td>
<td>29,842.8</td>
<td>382,730.7</td>
<td>[M-H]⁻</td>
<td>147,04, 162.06, 323.08</td>
<td></td>
<td></td>
</tr>
<tr>
<td>35</td>
<td><strong>f.e</strong> Kaempferol-3-O-glucoside</td>
<td>7,1817</td>
<td>447.09</td>
<td>758,031</td>
<td>5,389,442</td>
<td>[M-H]⁻</td>
<td>178,99, 284.02, 357.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>36</td>
<td><strong>f.e</strong> Isorhamnetin-3-O-glucoside</td>
<td>7,2792</td>
<td>477.1</td>
<td>3,955,113</td>
<td>20,922.760</td>
<td>[M-H]⁻</td>
<td>1788, 285, 299.01, 313.55, 315.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td><strong>p.a</strong> 3-(4-hydroxy-3-methoxyphenyl) prop-2-enoic acid</td>
<td>7,4109</td>
<td>195.06</td>
<td>6780.78</td>
<td>70,939.2</td>
<td>[M-H]⁻</td>
<td>109,06, 123.03, 149.11, 177.05</td>
<td></td>
<td></td>
</tr>
<tr>
<td>38</td>
<td><strong>c.o</strong> Scopoletin</td>
<td>7,4590</td>
<td>193.05</td>
<td>29,861.9</td>
<td>409,660.1</td>
<td>[M-H]⁻</td>
<td>91.04, 121.02, 161.02</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
Table 1 (Continued).

<table>
<thead>
<tr>
<th>Peak No.</th>
<th>Identification</th>
<th>RT (Min.)</th>
<th>m/z</th>
<th>Peak Height</th>
<th>Peak Area</th>
<th>Ion Mode</th>
<th>Formula</th>
<th>MS/MS</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td>39</td>
<td>Anthocyanidin-3-O-glycoside</td>
<td>7.6828</td>
<td>449.11</td>
<td>211,276</td>
<td>2,097,300</td>
<td>[M+H]^+</td>
<td>C_{20}H_{20}O_{11}</td>
<td>163.05</td>
<td>201.06, 241.05, 269.04, 287.05</td>
</tr>
<tr>
<td>41</td>
<td>Isorhamnetin-3-O-glucoside</td>
<td>7.8179</td>
<td>479.12</td>
<td>1,981,740</td>
<td>24,648,674</td>
<td>[M+H]^+</td>
<td>C_{23}H_{22}O_{12}</td>
<td>287.03</td>
<td>299.05, 301.03, 317.98</td>
</tr>
<tr>
<td>42</td>
<td>Kaempferol-3-O-α-L-rhamnoside</td>
<td>7.8462</td>
<td>431.1</td>
<td>12,659.7</td>
<td>140,206.6</td>
<td>[M-H]</td>
<td>C_{21}H_{20}O_{10}</td>
<td>268.03</td>
<td>285.08</td>
</tr>
<tr>
<td>43</td>
<td>Naringenin-7-O-glucoside</td>
<td>7.8914</td>
<td>435.13</td>
<td>1898.56</td>
<td>9114.708</td>
<td>[M+H]^+</td>
<td>C_{23}H_{22}O_{14}</td>
<td>147.04</td>
<td>153.01, 273.07</td>
</tr>
<tr>
<td>44</td>
<td>Quercetin</td>
<td>8.35</td>
<td>577.15</td>
<td>3264.66</td>
<td>34,088.91</td>
<td>[M-H]</td>
<td>C_{15}H_{10}O_{7}</td>
<td>151.00</td>
<td>178.99</td>
</tr>
<tr>
<td>45</td>
<td>Gossypin</td>
<td>9.57</td>
<td>481.10</td>
<td>3930.66</td>
<td>50,819.41</td>
<td>[M+H]^+</td>
<td>C_{23}H_{22}O_{13}</td>
<td>189.11</td>
<td></td>
</tr>
<tr>
<td>46</td>
<td>Quercetin</td>
<td>9.6202</td>
<td>301.04</td>
<td>16,805.9</td>
<td>249,482.8</td>
<td>[M-H]</td>
<td>C_{15}H_{10}O_{7}</td>
<td>153.00</td>
<td>181.07</td>
</tr>
<tr>
<td>47</td>
<td>Quercetin</td>
<td>9.7925</td>
<td>303.1</td>
<td>11,709.3</td>
<td>132,976.0</td>
<td>[M+H]^+</td>
<td>C_{15}H_{10}O_{7}</td>
<td>132.976</td>
<td>181.07</td>
</tr>
<tr>
<td>48</td>
<td>Anthocyanidin-3-O-((4'-O-(4'-O-E-coum)-α-rhamnopyranosyl-β-glucopyranosyl)-5-O-β-glucopyranosyl)</td>
<td>9.805</td>
<td>933.33</td>
<td>7586.56</td>
<td>81,087.66</td>
<td>[M]^+</td>
<td>C_{46}H_{46}O_{33}</td>
<td>275.20</td>
<td>317.06, 771.35, 903.31</td>
</tr>
<tr>
<td>49</td>
<td>Naringenin</td>
<td>10.098</td>
<td>271.06</td>
<td>132,825</td>
<td>2,140,767</td>
<td>[M-H]</td>
<td>C_{15}H_{10}O_{5}</td>
<td>177.07</td>
<td>201.05, 253.04</td>
</tr>
<tr>
<td>50</td>
<td>Daphnetin</td>
<td>10.52</td>
<td>177.0549</td>
<td>8722.55</td>
<td>108,885.21</td>
<td>[M-H]</td>
<td>C_{16}H_{10}O_{4}</td>
<td>117.03</td>
<td>133.02</td>
</tr>
<tr>
<td>51</td>
<td>Luteolin</td>
<td>10.939</td>
<td>285.04</td>
<td>78,611.9</td>
<td>946,757.6</td>
<td>[M-H]</td>
<td>C_{15}H_{10}O_{6}</td>
<td>171.04</td>
<td>220.07</td>
</tr>
<tr>
<td>52</td>
<td>3'-Methoxy-4',5,7-trihydroxyflavonol</td>
<td>11.14</td>
<td>315.05</td>
<td>268,655</td>
<td>2,243,987</td>
<td>[M-H]</td>
<td>C_{16}H_{12}O_{7}</td>
<td>225.10</td>
<td>271.03, 283.02, 300.02</td>
</tr>
<tr>
<td>53</td>
<td>Luteolin</td>
<td>11.401</td>
<td>287.05</td>
<td>16,984.9</td>
<td>139,318.8</td>
<td>[M+H]^+</td>
<td>C_{15}H_{10}O_{6}</td>
<td>117.07</td>
<td>147.04</td>
</tr>
<tr>
<td>54</td>
<td>Myricetin</td>
<td>11.426</td>
<td>319.13</td>
<td>3581.22</td>
<td>34,352.16</td>
<td>[M+H]^+</td>
<td>C_{19}H_{10}O_{6}</td>
<td>319.15</td>
<td></td>
</tr>
<tr>
<td>55</td>
<td>3'-Methoxy-4',5,7-trihydroxyflavonol</td>
<td>11.605</td>
<td>317.07</td>
<td>55,818.1</td>
<td>301,345.8</td>
<td>[M+H]^+</td>
<td>C_{16}H_{12}O_{7}</td>
<td>165.01</td>
<td>179.02, 271.05, 285.04</td>
</tr>
<tr>
<td>56</td>
<td>(+)-3'-4'5' 7-Pentahydroxyflavan</td>
<td>16.526</td>
<td>291.19</td>
<td>4260.22</td>
<td>52,578.86</td>
<td>[M+H]^+</td>
<td>C_{19}H_{10}O_{6}</td>
<td>123.12</td>
<td>141.07</td>
</tr>
<tr>
<td>57</td>
<td>3'-4'5'-Tetrahydroxy-7-methoxyflavone</td>
<td>20.093</td>
<td>317.12</td>
<td>96,989</td>
<td>983,757.1</td>
<td>[M+H]^+</td>
<td>C_{17}H_{12}O_{7}</td>
<td>201.15</td>
<td>317.11</td>
</tr>
</tbody>
</table>

Figure 1 Total ion chromatogram by LC-MS/MS of BRFE labeled with the tentatively identified active metabolites in (A) negative ion mode, (B) positive ion mode.

Figure 2 Base peak charts of major identified phenolic compounds of BRFE by LC-ESI-MS/MS in negative ion mode; (A) isorhamnetin 3-O-glucopyranoside, (B) delphinidin-3-O-β-glucopyranoside, and in positive ion mode; (C) isorhamnetin 3-O-glucopyranoside, (D) cyanidin-3, 5-di-O-glucoside.
other identified anthocyanidin 3-O-glycosides were cyanidin-3-glucoside, cyanidin-3-O-(2″-O-β-glucopyranosyl-β-glucopyranoside), petunidin-3-O-β-glucopyranoside, and petunidin-3-O-(6″-O-(4″-O-E-coum)-α-rhamnopyranosyl-β-glucopyranosyl)-5-O-β-glucopyranoside trifluoroacetate salt.

**Antibacterial Activity**
BRFE showed antibacterial activity against the tested isolates, and the MICs are shown in Figure 3. The MICs of ciprofloxacin (positive control) against the tested isolates ranged from 0.125 to 0.5 µg/mL. However, DMSO (negative control) did not exhibit any antimicrobial activity.

**Impact on Bacterial Membrane Permeability: Outer Membrane Permeability of Gram-Negative Bacteria**
Outer membrane permeability was studied in *S. dysenteriae*, *E. coli*, and *S. typhimurium* by detection of fluorescent NPN using a spectrofluorophotometer, as the fluorescence of NPN is detectable in the hydrophobic regions of bacteria, such as cell membranes.²³ BRFE (at 0.5 MIC) significantly increased NPN fluorescence, indicating a substantial increase (*p* < 0.001) in the outer membrane permeability, as shown in Figure 4A (a representative example).

**Inner Membrane Permeability**
If the inner membrane permeability increases, ONPG enters the bacterial cells and is converted by β-galactosidase, which is present in the bacterial cytoplasm, into O-nitrophenol (ONP).²⁴ ONP has a yellow color, and its amount can be detected by measuring the absorbance at OD = 420 over time. An illustrative example is shown in Figure 4B. The inner membrane permeability significantly increased (*p* < 0.001) after BRFE treatment (at 0.5 MIC).

**Impact on Bacterial Membrane Depolarization**
The impact of BRFE on membrane depolarization of the tested isolates was studied quantitatively using flow cytometry after staining the isolates with DiBAC4(3), a fluorescent compound that can enter depolarized cells and binds to intracellular proteins, resulting in increased fluorescence.²⁵ BRFE did not produce any significant changes in the membrane depolarization of the tested isolates, and an illustrative example is shown in Figure 5.

**Immunomodulatory Activity**
**MTT Assay**
The effect of BRFE (concentrations of 3.125, 6.25, 12.5, 25, 50, 100, 200, and 400 µg/mL) on PBMC viability was evaluated. The IC₅₀ against PBMCs was 84.9 ± 0.818 µg/mL, as shown in Figure 6.

**qRT-PCR**
The relative gene expression of inflammation-related enzymes (COX-2 and iNOS), cytokines (IL-6 and TNF-α), and the transcription factor NF-κB increased in LPS-stimulated PBMCs. Remarkably, treatment of LPS-stimulated PBMCs with BRFE at 0.5 IC₅₀ attenuated the upregulation of the gene expression of IL-6 and TNF-α. In addition, it significantly reduced the gene expression of

![Figure 3](https://doi.org/10.2147/JIR.S345780)
In vivo Studies
Effect on Oxidative Stress Markers
When compared to the control group (group 1), the ulcer group (group 2) had a sharp increase in gastric MDA levels but a significant reduction in gastric GSH levels ($p < 0.001$). Pretreatment with either BRFE (150 or 300 mg/kg: groups 3 and 4, respectively) significantly decreased gastric MDA levels compared with group 2 ($p < 0.001$). A significant increase in gastric GSH levels was observed in both groups 3 and 4 compared with group 2 ($p < 0.001$). The results are displayed in Tables S3 and S4 and Figure 8.

Effect on Cytoprotective Mediators
Gastric NO and PGE2 levels significantly reduced in group 2 compared with group 1 ($p < 0.001$). Compared with group 2, groups 3 and 4 exhibited a substantial increase in gastric NO and PGE2 levels ($p < 0.001$). The results are presented in Tables S5 and S6 and Figure 9.

qRT-PCR: Effect on IL-10 Gene Expression
The level of gene expression of IL-10 was $1.25 \pm 0.36$ in group 1 and $0.75 \pm 0.18$ in group 2 ($p < 0.001$). Compared...
with group 2, gene expression of IL-10 significantly increased in both groups 3 and 4 (0.96 ± 0.21 and 1.06 ± 0.2, respectively; \( p < 0.001 \)). There was a significant difference in the gene expression of IL-10 between group 4 and group 1. The results are presented in Table S7 and Figure 10A.

Effect on GPx Gene Expression
The level of gene expression of GPx was 1.34 ± 0.39 in group 1 and 0.75 ± 0.19 in group 2 \( (p < 0.001) \). When compared with group 2, both groups 3 and 4 showed a marked increase in the gene expression of GPx (1.02 ± 0.22 and 1.2 ± 0.13, respectively; \( p < 0.001 \)). There was a significant difference in the gene expression of GPx between group 4 and group 1. The results are presented in Table S8 and Figure 10B.

Effect on NF-κB Gene Expression
The level of gene expression of NF-κB was 0.81 ± 0.08 in group 1 and 1.75 ± 0.33 in group 2 \( (p < 0.001) \). Compared with group 2, there was a considerable decrease in the gene expression of NF-κB in both groups 3 and 4 \( (1.10 ± 0.25 \) and \( 0.83 ± 0.10, \) respectively; \( p < 0.001 \)). There was no notable difference in the gene expression of NF-κB between group 4 and group 1. The results are displayed in Table S9 and Figure 10C.
Effect on MPO Gene Expression
The level of gene expression of MPO was 0.81 ± 0.07 in group 1 and 1.86 ± 0.11 in group 2 \((p < 0.001)\). Compared with group 2, there was a significant decrease in the gene expression of MPO in both groups 3 and 4 \(1.07 ± 0.25\) and \(0.83 ± 0.10\), respectively; \(p < 0.001\). There was no substantial difference in the gene expression of MPO between group 4 and group 1 \((p = 0.97)\). The results are presented in Table S10 and Figure 10D.

Histopathological Studies
The histopathological results of the examined stomach tissues of groups 3 and 4 showed limited degenerative changes of the gastric mucosa induced by indomethacin compared with the positive control group. The area of mucosal necrosis and ulceration in the positive control group, as a marker of the severity of mucosal and submucosal cellular pathological changes, decreased in group 3. In addition, complete healing of the mucosal tissue was observed in group 4. Moreover, congestion and leukocytic cell infiltration were limited in groups 3 and 4. Mild submucosal edema was observed in group 4, as displayed in Figure 11.

Discussion
BRFE exhibited antibacterial potential against the tested isolates, which cause for GIT infections. \(S.\) \textit{dysenteriae} causes bacillary dysentery, which is the main cause of morbidity and mortality among children in many countries.\textsuperscript{71} \(E.\) \textit{coli} can cause intestinal diseases, especially enterohemorrhagic \(E.\) \textit{coli} (EHEC), enteropathogenic \(E.\) \textit{coli} (EPEC), enterotoxigenic \(E.\) \textit{coli} (ETEC), and enteroinvasive \(E.\) \textit{coli} (EIEC).\textsuperscript{1} \(S.\) \textit{enterica} serovar typhimurium is a common foodborne bacterium that can cause intestinal
inflammatory diseases and diarrhea; in addition, it results in thousands of deaths worldwide. S. aureus can produce staphylococcal enterotoxins that cause food poisoning.

For a greater understanding of the antibacterial activity of BRFE, we investigated its impact on the membrane properties of the tested isolates. The outer membrane is present only in Gram-negative bacteria, and it plays an important role in limiting antibiotic access into bacterial cells. BRFE resulted in a substantial increase in the outer membrane permeability in the tested Gram-negative bacteria. The inner membrane is present in both Gram-positive and Gram-negative bacteria. Disrupting the inner membrane by an antimicrobial agent could inhibit many important processes, which would result in a serious assault on bacterial cells. BRFE significantly increased inner membrane permeability in the tested isolates. Membrane potential dissipation is a mechanism of action of many antimicrobial compounds; thus, we investigated the impact of BRFE on the membrane potential of the tested isolates using flow cytometry and found an insignificant change.

PBMCs are blood cells, like lymphocytes and macrophages, having round nuclei. LPS is extracted from the outer membrane of Gram-negative bacteria and is a strong stimulator for macrophages. LPS-stimulated macrophages produce inflammatory mediators, such as prostaglandins and NO, in addition to many inflammatory cytokines, such as IL-6 and TNF-α. Prostaglandins are produced by COX-2 enzyme activity on arachidonic acid, and NO is produced by iNOS activity on the L-arginine amino acid. The production of both prostaglandins and NO are produced by LPS-activated macrophages increases as a result of upregulation of the expression of genes encoding COX-2 and iNOS. Moreover, the NF-κB transcription factor induces proinflammatory genes to produce high amounts of proinflammatory mediators in LPS-activated macrophages. Overexpression of these bioactive molecules occurs during an inflammatory reaction and could result in detrimental effects on tissues. Hence, inhibition of these interactions offers a good therapeutic effect by decreasing the harmful effects of inflammation, especially GIT inflammatory diseases.

We also investigated the immunomodulatory effect of BRFE on LPS-stimulated PBMCs. After determining the IC$_{50}$ of BRFE against PBMCs, the LPS-stimulated PBMCs were treated with BEFR at 1/2 IC$_{50}$ and the

---

Figure 10: Bar chart showing the level of expressed genes of ulcer treated groups with 150 mg/kg and 300 mg/kg of BRFE compared to control group and ulcer induced group (untreated); (A) IL-10 gene, (B) GPx gene, (C) NF-κB gene and (D) MPO gene. The symbol * represents a significant change.
relative gene expression of COX-2, iNOS, IL-6, TNF-α, and NF-κB was determined using untreated LPS-stimulated PBMCs as controls. BRFE attenuated the upregulation of the gene expression of COX-2, iNOS, IL-6, TNF-α, and NF-κB.

We aimed to investigate BRFE’s gastroprotective efficacy and probable mechanisms of action using an indomethacin-induced gastric ulcer model in rats. Indomethacin was our first choice of drug to be used as it has a higher ulcerogenic potential than other nonsteroidal anti-inflammatory drugs (NSAIDs). BRFE had a dose-dependent effect and provided significant protection against ulcer development. Oral administration of indomethacin causes gastric ulcers in a variety of ways, including suppression of prostaglandin biosynthesis, depletion of gastric mucosal blood flow, and increase in the local inflammatory response, including the over secretion of pro-inflammatory mediators and cytokines, as well as the impairment of local defensive factors.

Figure 11 Microscopic pictures of H&E-stained rats’ stomachs: (A) The control group showing normal glandular gastric mucosa. (B) The untreated positive control group induced by indomethacin showing large area of mucosal necrosis and ulceration (thick black arrow) associated with marked submucosal edema (*), congestion (red arrow), and leukocytic cells infiltration (black arrow). (C) The treated group with BRFE (150 mg/kg) showing small area of mucosal necrosis and ulceration (thick black arrow) associated with milder submucosal edema (*), congestion (red arrow), and leukocytic cells infiltration (black arrow). (D) The treated group with BRFE (300 mg/kg) showing very mild submucosal edema (*) and very few leukocytic cells infiltration (black arrow). The left panel is with low magnification X: 100 bar 100 and the right panel is with high magnification X: 400 bar 50.
Neutrophils are innate immune system specialized cells that aid in host defense through phagocytosis and the production of reactive oxygen species (ROS). Neutrophil activation and infiltration in the stomach lead to the creation of lesions. MPO is a heme peroxidase found in neutrophil granules, and its activity reflects the number of neutrophils present in tissues. In this study, BRFE inhibited neutrophil infiltration in the stomach mucosa by decreasing the activity as well as expression of MPO.

The endogenous antioxidant system of GSH and GPx can be used to scavenge ROS and keep them at healthy levels. As BRFE treatment did not affect other parameters, it only enhanced the activity and gene expression of GPx, an enzyme that functions by oxidizing GSH to glutathione disulfide. This suggests that BRFE has only a minor antioxidant effect.

The main regulator of transcription of numerous genes implicated in inflammation, NF-κB, is activated when ROS is produced. NF-κB is activated during the formation of a stomach ulcer caused by indomethacin, and it promotes the production of inflammatory cytokines such as TNF-α, IL-6, and IL-1. Inhibiting NF-κB expression, in addition to making this transcription factor a target for the treatment of inflammatory disorders, is a critical step in preventing stomach ulcer formation.

Our findings showed that BRFE increased the local level of IL-10, but not its expression level, and this is following Basak and Hoffman who found that IL-10 inhibits the synthesis of inflammatory cytokines suppressing the inflammatory response. In our investigation, BRFE partially restored stomach MDA and GSH levels with a significant difference from the control values. By scavenging hydroxyl radicals BRFE has antioxidant properties and inhibits lipid peroxidation and interacting with hypochlorous acid, the most damaging oxidant. Our findings are consistent with El-Ashmawy et al as with a single dose of indomethacin causing a large rise in gastric MDA and a considerable drop in gastric GSH.

PGE2 and NO, two gastroprotective mediators, were shown to be considerably lower in the ulcer group in our investigation. On the contrary, rats treated with BRFE showed a considerable improvement in stomach levels of PGE2 and NO. Reduced PGE2 production and disruption of NO may play a role in the development of gastric ulcers caused by NSAIDs like indomethacin. PGE2 protects the stomach mucosa by boosting mucus secretion, lowering acid secretion, and preserving the blood flow. Due to the vasodilatation function of NO, it can control the stomach pH and increases the blood flow.

In our ulcer model, histopathological analysis of gastric tissue revealed apparent ulcer injury. The results indicated a reduction of pathological degenerative cellular changes of mucosal and submucosal tissues especially at the treatment dose of 300 mg/kg of BRFE. These findings were in line with the considerable increase in stomach levels of the inflammatory mediators (NF-κB and MPO). Different inflammatory mediators are believed to be involved in the pathogenesis of indomethacin-induced stomach ulcers by triggering neutrophil infiltration. The current histopathological findings clarified the gastroprotective effects of BRFE, showing relatively normal mucosa in treated rats.

According to data of LC/MS, it was found that BRFE contained several flavonoids and phenolic compounds asisorhamnetin, luteolin, kaempferol derivatives that were reported to inhibit NO production and explain the anti-inflammatory and gastroprotective effects of BRFE. Luteolin and kaempferol derivatives were reported to have strong inhibitory effects on NO production and these results are consistent with the inhibition of NO in LPS stimulated macrophages. Our results also were consistent with previously reported data about the antimicrobial effect of different flavonoids or flavonoid glycosides as quercetin, luteolin, isorhamnetin, naringenin, Kaempferol, and anthocyanins derivatives.

Conclusion

In the current investigation, the phytoconstituents of the B. rapa flower extract (BRFE) were identified using LC-MS/MS for the first time with identification of 57 compounds. BRFE proved to have antibacterial activity against the pathogenic bacteria that cause GIT infections by increasing the outer and inner membrane permeability. It also showed an immunomodulatory activity on lipopolysaccharide-stimulated peripheral blood mononuclear cells. Moreover, BRFE exhibited an anti-inflammatory activity required for maintaining the gastric mucosa homeostasis in an indomethacin-induced gastric ulcer in rats. Therefore, it could keep the required balance between aggressive and defensive factors in the stomach. Therefore, BRFE could be a future source for novel therapeutical drugs with an activity on the GIT infections as well as the gastric ulcer. Further future studies are recommended to isolate the responsible active ingredients of BRFE that has the main activity on the peptic ulcer. In addition, it is important to formulate BRFE in a pharmaceutical dosage form to maximize the practical incorporation of BRFE in the peptic ulcer treatment regimens.
Supplementary Materials

The following data are available online, Table S1: Sequences of the utilized primers in the immunomodulatory activity, Table S2: Sequences of the utilized primers in the in vivo studies, Table S3: MDA level within the control and the experimental groups, Table S4: GSH level within the control and the experimental groups, Table S5: PGE2 level within the control and the experimental groups, Table S6: Nitric oxide level within the control and the experimental groups, Table S7: IL-10 gene expression within the control and the experimental groups, Table S8: GPX level within the control and the experimental groups, Table S9: NF-KB level within the control and the experimental groups, Table S10: MPO activity within the control and the experimental groups, Table S11: B-actin level within the control and the experimental groups.

Acknowledgments

This work was funded by the Deanship of Scientific Research at Prince Nourah bint Abdulrahman University, through the Research Groups Program Grant no. (RGP-1440-0022) (2). The authors, therefore, gratefully acknowledge the DSR technical and financial support.

Funding

This work was funded by the Deanship of Scientific Research at Prince Nourah bint Abdulrahman University, through the Research Groups Program Grant no. (RGP-1440-0022) (2).

Disclosure

The authors report no conflicts of interest in this work.

References


